Ascendis Pharma AS 2025 SR
The report highlights Ascendis Pharma's corporate responsibility and ESG activities for the fiscal year 2025. Key achievements include the successful launch of Yorvipath in the U.S., Austria, and Spain, and the expansion of Skytrofa for adult growth hormone deficiency in the U.S. The company also submitted regulatory applications for TransCon CNP in both the U.S. and EU. On the environmental front, Ascendis Pharma reported its Scope 1 and Scope 2 emissions, showing a total of 1,124 tCO2e (location-based) due to business growth. Additionally, the company grew its workforce to over 1,180 employees while maintaining equal gender representation across all management levels.
Company: Ascendis Pharma AS
Sector: Health Care
Country: Denmark
Year: 2025
Type: SR
Pages: 52
Ascendis Pharma AS
Corporate Responsibility And P ESG Report
The report highlights Ascendis Pharma's corporate responsibility and ESG activities for the fiscal year 2025. Key achievements include the successful launch of Yorvipath in the U.S., Austria, and Spain, and the expansion of Skytrofa for adult growth hormone deficiency in the U.S. The company also submitted regulatory applications for TransCon CNP in both the U.S. and EU. On the environmental front, Ascendis Pharma reported its Scope 1 and Scope 2 emissions, showing a total of 1,124 tCO2e (location-based) due to business growth. Additionally, the company grew its workforce to over 1,180 employees while maintaining equal gender representation across all management levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees